BIOSYENT INC (RX.CA) Stock Income Statement
TSX-V:RX - TSX Venture Exchange - CA0906901081 - Common Stock - Currency: CAD
| 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 35.03M | 31.59M | 27.93M | 28.62M | 22.33M | |||
| Cost Of Goods | 7.17M | 5.99M | 5.07M | 5.98M | 4.91M | |||
| Gross Profit | 27.86M | 25.60M | 22.86M | 22.64M | 17.42M | |||
| Operating Expenses | 18.79M | 18.06M | 15.85M | 14.39M | 12.30M | |||
| Research and Development | 171.40K | 83.30K | 121.00K | 160.70K | 287.70K | |||
| Selling, General, and Administrative Expenses | 18.03M | 17.53M | 15.27M | 13.77M | 11.50M | |||
| Operating Income | 9.06M | 7.53M | 7.01M | 8.25M | 5.13M | |||
| Interest Income/Expense | 1.15M | 999.60K | 523.80K | 5.80K | 111.40K | |||
| Other Income/Expense | N/A | N/A | 0.00 | 125.00K | N/A | |||
| Non Recurring Items | -430.00K | N/A | -106.00K | N/A | 0.00 | |||
| Income Before Taxes | 9.78M | 8.53M | 7.43M | 8.38M | 5.24M | |||
| Income Tax | 2.51M | 2.07M | 1.97M | 2.10M | 1.44M | |||
| Net Income | 7.27M | 6.46M | 5.46M | 6.28M | 3.80M | |||
| EBITDA | 9.65M | 7.99M | 7.46M | 8.70M | 5.64M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | 0.62 | 0.53 | 0.44 | 0.49 | 0.29 | |||
| Non GAAP EPS | 0.62 | N/A | 0.43 | 0.49 | 0.29 | |||
| Statistics | ||||||||
| Gross Profit Margin | 79.52% | 81.03% | 81.85% | 79.10% | 78.02% | |||
| Profit Margin | 20.75% | 20.45% | 19.55% | 21.95% | 16.99% | |||
| Operating Profit Margin | 25.88% | 23.85% | 25.11% | 28.82% | 22.95% | |||
All data in CAD